Accelerating the Future of Gene Therapy
High-yield AAV manufacturing, a world-class cGMP facility, and seamless support—from concept to commercial.

What Drives us
Our Mission
Our mission is bold because your therapies shape the future. Enabling access to life-changing gene therapies by helping to bring them from concept to reality fuels everything we do, from our technologies and team to our facility. We are here to help you deliver your therapy to the patients who need it most.

Why Developers Choose Us
Selecting the right CDMO is a critical decision. The partnership you build matters, and the stakes couldn’t be higher. More than 50 developers have trusted Forge to help advance their programs. Here’s why.

Manufacturing Innovation
Innovation That Powers Your Progress
Our investments in manufacturing R&D have led to real advantages for developers through novel technologies in our FUEL™ platform, including our Ignition Cells™, pEMBR™ 2.0 Ad Helper, modified rep/caps, and improved analytics for AAV characterization. Everything is designed to help you develop, manufacture, and deliver transformative therapies faster, safer, and to more patients.

Where AAV comes first
Our AAV Focus Is Your Advantage
Everything we build is focused on advancing AAV. From our novel technologies and state-of-the-art facility to the AAV experts who lead our teams, every part of Forge is designed with AAV in mind. This singular focus allows us to deliver deeper expertise, better solutions, and stronger support for your gene therapy program.

Idea to impact partnership
Beyond Manufacturing. Beside You Every Step.
At Forge, we are a true partner, working alongside innovators from the earliest stages of discovery through cGMP success. Our services are built to support every step, starting with molecular development, through product-specific process development; and even regulatory support, including IND review. We are committed to partnering with you not just to manufacture your therapy, but to help guide its entire journey.
50+
More than 50 clients supported across all stages
97%
97% of clients use our technologies
500+
Over 500 batches manufactured to date
35+
Expertise in supporting more than 35 indications

our facility
Where Great Science Meets Serious Scale
To bring gene therapies to patients, you need a facility built for scale, flexibility, and unwavering compliance. The Hearth, Forge’s 200,000+ sq. ft. cGMP facility, is one of the largest manufacturing sites dedicated to AAV. With 20 cGMP suites and bioreactors ranging from 50 to 5,000L, it’s intentionally designed to increase throughput and support efficient production.

Let’s Power Your Progress
Guided by your goals, we help bring your therapy to patients with purpose, precision, and true partnership.
Hot off the Forge
-
Fractyl Health will leverage Forge’s FUEL™ platform to manufacture AAV for Rejuva, Fractyl’s pancreatic gene therapy platform for patients with…
-
Oral and poster presentations will highlight data demonstrating the enhanced productivity, recovery, and consistent quality of Forge’s FUEL™ AAV manufacturing…
-
“We’re proud to support Affinia’s vision of bringing hope to patients affected by cardiomyopathy through their innovative gene therapy.”
-
FUEL™ platform can achieve a 2-6x increase in productivity compared to industry standard, and includes pEMBR 2.0™ Ad helper and…